Jiuping Ji - Concepedia

Author

Jiuping Ji

National Cancer Institute ORCID

Also Known As

Jiuping (Jay) Ji, Jiuping Ji

197

Publications

6.8K

Citations

H-Index

Concepts

All Affiliations

National Cancer Institute Center for Cancer Research Frederick National Laboratory for Cancer Research Leidos (United States)National Institutes of Health

About

Jiuping Ji is an author at National Cancer Institute specializing in medicine, pharmacology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	990
2	Biochemistry	3	3	785
3	Natural Sciences	2	2	760
4	Cell Biology	2	2	118
5	Chemical Biology	1	1	745

Jiuping Ji

Publications

6.5K

Citations

H-Index

Page 1

	Year	Citations
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors Junko Murai, Shar-yin N. Huang, Benu Brata Das, Cancer Research	2012	2.1K
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib Junko Murai, Shar-yin N. Huang, Amèlie Renaud, Molecular Cancer Therapeutics Molecular PharmacologyMedicinal ChemistryBioorganic ChemistryCatalytic Parp InhibitionBiochemistry	2013	745
Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i> -Mutated Mouse Mammary Tumors Janneke E. Jaspers, Ariena Kersbergen, Ute Boon, Cancer Discovery	2012	510
Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies Shivaani Kummar, Robert J. Kinders, Martin Gutierrez, Journal of Clinical Oncology	2009	324
Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors T. Khanh, Deborah Wilsker, Jiuping Ji, Journal of Clinical Oncology	2015	317
Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition Junko Murai, Yiping Zhang, Joel Morris, Journal of Pharmacology and Experimental Therapeutics	2014	278
Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas Shivaani Kummar, Alice P. Chen, Jiuping Ji, Cancer Research	2011	252
A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas Shivaani Kummar, Jiuping Ji, Robert J. Morgan, Clinical Cancer Research	2012	201
Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses Jung Min Lee, John L. Hays, Christina M. Annunziata, JNCI Journal of the National Cancer Institute	2014	183
Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors Anish Thomas, Christophe E. Redon, Linda Sciuto, Journal of Clinical Oncology	2017	166

Page 1